At the same time, several lncRNAs (e.g., linc-ROR [15], GAS5 [16, 17] and linc-DYNC2H1-4 [18]) have been identified as ceRNAs to confer drug resistance in pancreatic cancer. This evidence concerns the gene DYNC2H1 and pancreatic neoplasm.